vs

Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $43.5M, roughly 1.0× DYNEX CAPITAL INC). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs 13.8%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs 7.3%).

Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

DX vs PACB — Head-to-Head

Bigger by revenue
PACB
PACB
1.0× larger
PACB
$44.6M
$43.5M
DX
Growing faster (revenue YoY)
DX
DX
+517.5% gap
DX
531.3%
13.8%
PACB
Faster 2-yr revenue CAGR
DX
DX
Annualised
DX
75.8%
7.3%
PACB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DX
DX
PACB
PACB
Revenue
$43.5M
$44.6M
Net Profit
$-40.4M
Gross Margin
37.1%
Operating Margin
-92.3%
Net Margin
-90.4%
Revenue YoY
531.3%
13.8%
Net Profit YoY
-1802.7%
EPS (diluted)
$1.59
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DX
DX
PACB
PACB
Q4 25
$43.5M
$44.6M
Q3 25
$30.6M
$38.4M
Q2 25
$23.1M
$39.8M
Q1 25
$17.1M
$37.2M
Q4 24
$39.2M
Q3 24
$40.0M
Q2 24
$36.0M
Q1 24
$-3.2M
$38.8M
Net Profit
DX
DX
PACB
PACB
Q4 25
$-40.4M
Q3 25
$150.4M
$-38.0M
Q2 25
$-13.6M
$-41.9M
Q1 25
$-3.1M
$-426.1M
Q4 24
$2.4M
Q3 24
$-60.7M
Q2 24
$-173.3M
Q1 24
$40.1M
$-78.2M
Gross Margin
DX
DX
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
DX
DX
PACB
PACB
Q4 25
-92.3%
Q3 25
-101.1%
Q2 25
-112.8%
Q1 25
-1154.5%
Q4 24
-390.1%
Q3 24
-160.3%
Q2 24
-488.3%
Q1 24
-209.6%
Net Margin
DX
DX
PACB
PACB
Q4 25
-90.4%
Q3 25
491.3%
-98.9%
Q2 25
-58.8%
-105.4%
Q1 25
-18.0%
-1146.8%
Q4 24
6.0%
Q3 24
-151.9%
Q2 24
-481.3%
Q1 24
-1256.8%
-201.4%
EPS (diluted)
DX
DX
PACB
PACB
Q4 25
$1.59
$-0.11
Q3 25
$1.08
$-0.13
Q2 25
$-0.14
$-0.14
Q1 25
$-0.06
$-1.44
Q4 24
$-0.44
Q3 24
$-0.22
Q2 24
$-0.64
Q1 24
$0.64
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DX
DX
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$531.0M
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.5B
$5.3M
Total Assets
$17.3B
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DX
DX
PACB
PACB
Q4 25
$531.0M
$279.5M
Q3 25
$491.0M
$298.7M
Q2 25
$387.5M
$314.7M
Q1 25
$327.4M
$343.1M
Q4 24
$389.9M
Q3 24
$471.1M
Q2 24
$509.8M
Q1 24
$295.7M
$561.9M
Stockholders' Equity
DX
DX
PACB
PACB
Q4 25
$2.5B
$5.3M
Q3 25
$2.0B
$36.1M
Q2 25
$1.6B
$61.5M
Q1 25
$1.4B
$91.6M
Q4 24
$506.6M
Q3 24
$453.1M
Q2 24
$492.7M
Q1 24
$958.5M
$649.0M
Total Assets
DX
DX
PACB
PACB
Q4 25
$17.3B
$784.1M
Q3 25
$14.2B
$803.2M
Q2 25
$11.3B
$825.5M
Q1 25
$9.0B
$860.8M
Q4 24
$1.3B
Q3 24
$1.5B
Q2 24
$1.5B
Q1 24
$6.3B
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DX
DX
PACB
PACB
Operating Cash FlowLast quarter
$120.8M
$-19.1M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-44.6%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DX
DX
PACB
PACB
Q4 25
$120.8M
$-19.1M
Q3 25
$68.3M
$-18.7M
Q2 25
$31.9M
$-29.4M
Q1 25
$6.4M
$-44.1M
Q4 24
$-30.6M
Q3 24
$-45.5M
Q2 24
$-54.3M
Q1 24
$-17.1M
$-75.7M
Free Cash Flow
DX
DX
PACB
PACB
Q4 25
$-19.9M
Q3 25
$-18.8M
Q2 25
$-29.9M
Q1 25
$-45.4M
Q4 24
$-32.3M
Q3 24
$-46.3M
Q2 24
$-55.7M
Q1 24
$-79.6M
FCF Margin
DX
DX
PACB
PACB
Q4 25
-44.6%
Q3 25
-48.9%
Q2 25
-75.3%
Q1 25
-122.3%
Q4 24
-82.3%
Q3 24
-115.7%
Q2 24
-154.8%
Q1 24
-205.0%
Capex Intensity
DX
DX
PACB
PACB
Q4 25
1.9%
Q3 25
0.2%
Q2 25
1.4%
Q1 25
3.7%
Q4 24
4.1%
Q3 24
2.0%
Q2 24
4.1%
Q1 24
10.0%
Cash Conversion
DX
DX
PACB
PACB
Q4 25
Q3 25
0.45×
Q2 25
Q1 25
Q4 24
-12.93×
Q3 24
Q2 24
Q1 24
-0.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DX
DX

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons